PQ 438
438. Deputy Marc MacSharry asked the Minister for Health the difference in approach taken by Irish and other European assessors of a medicine's clinical and cost effectiveness with regard to treatments for rare disease in circumstances in which certain medicines are readily available in over 22 other European countries but have been refused access here; and if he will make a statement on the matter. [42315/17]
Introduced
10 October 2017
Last action
—
Status
written
Sponsors
—
Subjects
Discovery layer
Source updated
10 October 2017
Summary
438. Deputy Marc MacSharry asked the Minister for Health the difference in approach taken by Irish and other European assessors of a medicine's clinical and cost effectiveness with regard to treatments for rare disease in circumstances in which certain medicines are readily available in over 22 other European countries but have been refused access here; and if he will make a statement on the matter. [42315/17]
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
1 official file
Medicinal Products Reimbursement
Medicinal Products Reimbursement
xml · EN · 10 October 2017
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.oireachtas.ie/en/debates/question/2017-10-10/438/
- Open data entity: https://data.oireachtas.ie/ie/oireachtas/question/2017-10-10/pq_438